Clinical Trial Update: Monocentric Trial: Stem Cell Emergency Life Threatening Limbs Arteriopathy (SCELTA) [Phase 2, Phase 3]

View source ↗

Summary

The SCELTA trial, a monocentric Phase 2/3 study of stem cell therapy for critical limb ischemia, has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Critical Limb Ischemia

Drugs mentioned

• SCELTA stem cell therapy

Snippet

Sponsor: University of Florence | Conditions: Critical Limb Ischemia | Phase 2, Phase 3 | Status: COMPLETED